PETREL for Astrophysics and Carbon Business

A multi-purpose 50kg class microsatellite hosting astrophysical mission and earth remote sensing, PETREL , will be launched in 2023. In the night side, PETREL observe the ultra-violet sky with a wide-field telescope covering 50 deg^2 for surveying transient objects related to supernovae, tidal disruption events, and gravitational wave events. Our UV telescope can detect the early phase UV emission from a neutron star merger occurred within 150 Mpc. In addition to the satellite observation, PETREL sends a detection alert including the coordinate and brightness of the UV transient to the ground via the real time communication network within several minutes after detection to conduct follow-up observations with the collaborating ground based observatories over the world. In the day side, PETREL observes the surface of the earth by using the tunable multi-spectral cameras and a ultra-compact hyperspectral camera. Our potential targets are the tropical forests (Green Carbon) and coastal zones (Blue Carbon) in the tropical areas to evaluating the global biological carbon strages. For this purpose PETREL will conduct multiple scale mapping collaborating with drones and small aircraft not only satellite. The obtained data will be used for academical research and for business applications. The technical difficulty of this satellite is that carries out multi-purpose with different requirements, such as astronomical observations which requires a quite high attitude stability and the earth observations requiring a high pointing accuracy, with limited resources. If it is possible, a novel small satellite system or a business style can be realized that can share the payload with academia and industry. PETREL has been adopted as Innovative Satellite Technology Demonstration Program No.3 led by JAXA, and development is underway with the aim of launching in FY2023

ドウニュウ カガク リョウホウ ニテ コンチ セツジョ ガ カノウ トナッタ ケイブ ショクドウガン ノ 1レイ

　症例は50歳代，男性．咽頭痛，嚥下障害を主訴に近医受診し，上部消化管内視鏡検査にて頸部食道に1/4周性のtype3病変(squamous cell carcinoma)と食道胃接合部に0-IIa+IIc病変(adenocarcinoma)を指摘され，当院当科紹介となった．造影CT検査にて左頸部に原発巣と一塊となった腫瘤を認め，左総頸動脈及び気管への浸潤を認めた．精査の結果，頸部食道癌cT4bN2M0 cStageIVa，バレット食道腺癌cT1bN0M0 cStageIと診断し，切除不能局所進行食道癌であり導入化学療法の方針とした．DCF(Docetaxel/Cisplatin/5-Fluorouracil) 療法3コースで病変の縮小が得られ，頸部腫瘍は長径37mmから17mmとなり，総頸動脈の浸潤が解除されたため，根治術を行う方針とした．手術は咽頭喉頭食道全摘，頸部縦隔腹部リンパ節郭清，後縦隔経路遊離空腸付加胃管再建，腸瘻造設術を施行した．術中偶発症なく，手術時間846分，出血量670mLであった．病理組織学的検査では，頸部食道癌ypT4aN2M0 ypStegeIII，治療効果Grade 1b，バレット食道癌ypT1b-SM2N0M0 ypStageI，治療効果Grade 1aであった．術後経過は概ね良好で術後9日目より経口摂取を開始し，術後18日目に退院となった．　切除不能局所進行食道癌に対する標準治療は化学放射線療法であるが，近年，DCF療法による導入化学療法後の外科的切除の有用性が報告されている．今回，導入化学療法により根治切除可能であった頸部食道癌，食道腺癌の重複例を経験したため報告する．　A 58-year-old man with sore throat and dysphagia revealed type 3 lesion in cervical esophagus and 0-IIa+IIc lesion in esophagogastric junction on upper gastrointestinal endoscopy. Histopathologic examination of biopsy specimens showed squamous cell carcinoma at cervical esophagus and adenocarcinoma at esophagogastric junction. Computed tomography suggested that the large tumor in left neck infiltrated into the common carotid artery and trachea. According to these findings, we diagnosed locally advanced unresectable cervical esophageal cancer (cT4bN2M0, cStageIVa) and Barret’s esophageal adenocarcinoma (cT1bN0M0, cStageI), and decided to perform induction chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil (DCF). After 3 courses of that, the primary tumor decreased from 37 mm to 17 mm as major axis and released infiltration into the common carotid artery. Therefore, we performed conversion surgery, pharyngolaryngectomy and total esophagectomy. Histopathological findings showed cervical esophageal cancer (ycT4aN2M0, ycStageIVa) and Barret’s esophageal adenocarcinoma (ycT1b-SM2N0M0, ycStageI). The postoperative course was uneventful, he resumed eating 9 days after surgery and was discharged 18 days after surgery.　Conversion surgery after induction chemotherapy for locally advanced unresectable esophageal cancer may contribute to radical resection and better clinical outcome

PD-L1の高発現とヒト髄芽腫におけるCD8陽性T細胞浸潤と予後の相関

京都大学0048新制・課程博士博士(医学)甲第21302号医博第4391号新制||医||1030(附属図書館)京都大学大学院医学研究科医学専攻(主査)教授 生田 宏一, 教授 椛島 健治, 教授 杉田 昌彦学位規則第4条第1項該当Doctor of Medical ScienceKyoto UniversityDFA

Comparing Transition Procedures in Modified Simulated-Annealing-Based Synthetic Reconstruction Method without Samples

In this paper, we modify a synthetic reconstruction (SR) method without samples. The synthetic reconstruction method is a method to generate attributes of population such as age, sex and kinship within a family according to available statistics. Although the original SR method employs some individual samples that are collected to make a statistics, it is criticized that generated attributes are only within the samples used in the reconstruction process. In this paper, we employ a simulated annealing-based SR method without samples. We compare two types of generation methods of a candidate solution in a search of simulated annealing: changing age of an agent (age-change) or swapping ages of two agents (age-swap). Results of synthetic reconstruction show that age-change is better when we limit the number of search. On the other hand, age-swap is better when we have enough number of search for reconstructing a population

Efficient Attenuation of Dextran Sulfate Sodium-Induced Colitis by Oral Administration of 5,6-Dihydroxy-8Z,11Z,14Z,17Z-eicosatetraenoic Acid in Mice

5,6-dihydroxy-8Z,11Z,14Z,17Z-eicosatetraenoic acid (5,6-DiHETE) is an eicosapentaenoic acid-derived newly discovered bioactive anti-inflammatory lipid mediator having diverse functions. Here, we assessed the potential of orally administered 5,6-DiHETE in promoting healing of dextran sulfate sodium (DSS)-induced colitis in mice. We measured the plasma concentrations of 5,6-DiHETE in untreated mice before and 0.5, 1, 3, and 6 h after its oral administration (150 or 600 μg/kg) in mice. Mice developed colitis by DSS (2% in drinking water for 4 days), and 5,6-DiHETE (150 or 600 μg/kg/day) was orally administered from day 9 to 14. Next, the faecal hardness and bleeding were assessed, and the dissected colons on day 14 via H&E staining. The plasma concentration of 5,6-DiHETE reached 25.05 or 44.79 ng/mL 0.5 h after the administration of 150 or 600 μg/kg, respectively, followed by a gradual decrease. The half-life of 5,6-DiHETE was estimated to be 1.25–1.63 h. Diarrhoea deteriorated after day 3 and peaked on day 5, followed by a gradual recovery. Histological assessment on day 14 showed DSS-mediated granulocyte infiltration, mucosal erosion, submucosal edema, and cryptal abscesses in mice. Oral administration of 150 or 600 μg/kg/day of 5,6-DiHETE accelerated the recovery from the DSS-induced diarrhoea and significantly ameliorated colon inflammation. The therapeutic effect of 600 μg/kg/day 5,6-DiHETE was slightly stronger than that by 150 μg/kg/day. Our study reveals attenuation of DSS-induced colitis in mice by the oral administration of 5,6-DiHETE dose-dependently, thereby suggesting a therapeutic potential of 5,6-DiHETE for inflammatory bowel disease